---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-211860"
form_type: "8-K"
ticker: "AMGN"
cik: "0000318154"
company_name: "AMGEN INC"
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T04:33:35.115398+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Amgen to acquire ChemoCentryx for $52/share (~$3.7B) including TAVNEOS

## Summary
- Amgen will pay $52 per share in cash, enterprise value ~$3.7B; deal unanimously approved by both boards.
- TAVNEOS (avacopan) is a first-in-class oral C5aR inhibitor approved Oct 2021 for ANCA-associated vasculitis; Q1 2022 US sales $5.4M.
- Transaction expected to close Q4 2022, subject to ChemoCentryx stockholder approval, HSR clearance, and other conditions.
- ChemoCentryx must pay Amgen a termination fee of ~$119M if it terminates for a superior proposal or under certain circumstances.
- Acquisition includes early-stage pipeline: three inflammatory disease candidates and an oral checkpoint inhibitor for cancer.

## SEC filing metadata
- accession: 0001193125-22-211860
- form_type: 8-K
- ticker: AMGN
- cik: 0000318154
- company_name: AMGEN INC
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318154/000119312522211860/0001193125-22-211860-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318154/000119312522211860/d346334d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-211860
- JSON: https://secwatch.observer/filing/0001193125-22-211860.json
- Plain text: https://secwatch.observer/filing/0001193125-22-211860.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.